Skip to main content

Table 6 Ongoing Clinical Trials Investigating Immunotherapy in SCLC

From: Lung cancer immunotherapy: progress, pitfalls, and promises

Trial Identifier (NCT reference)

Drug/Target

Phase

Treatment Regimen

Limited stage

 NCT02402920

Pembro/PD-1

I

MK-3475 + PE + Thoracic RT

 NCT02934503

Pembro/PD-1

II

Pembro + PE + Thoracic RT

Extensive stage

 NCT03066778

Pembro/PD-1

III

Pembro + PE vs Placebo + PE

 NCT02763579

Atezo/PD-L1

I/II

Atezo + Carboplatin + Etoposide Vs. Placebo + Carboplatin + Etoposide

Extensive stage-Maintenance

 NCT03043599

Ipi Nivo/CTLA-4 PD-1

I/II

Consolidative Ipi + Nivo and maintenance Nivo with Thoracic RT after platinum-based chemotherapy

 RAPTOR (NCT04402788)

Atezo

II/III

Atezo vs Atezo + RT

Extensive stage-Second-line and beyond

 NCT03026166

Ipi Nivo/CTLA-4 PD-1

I/II

Rova-T and Nivo or Rova-T and Nivo plus Ipi 1 mg/kg or Rova-T and Nivo plus Ipi 3 mg/kg

  1. Abbreviations: Pembro Pembrolizumab, PE platinum/etoposide, Rt Radiotherapy, Atezo Atezolizumab, PD-1 Programmed cell death-1, Ipi ipilimumab, Nivo Nivolumab, CTLA-4 cytotoxic T-lymphocyte antigen, Rova-T Rovalpituzumab tesirine, Durva Durvalumab
Back to article page

Molecular Cancer

ISSN: 1476-4598